Preclinical experiments were performed using CAR T-cells in the treatment of solid tumors, including brain and prostate cancers; moreover, clinical trials are also ongoing against CD133 and EGFR (epidermal growth receptor), which are frequently found to be upregulated in these malignant tumors [59]. Here, PROM1 is linked to cancer.